Loss of targeted antigens (such as BCMA) and soluble circulating antigens represent a challenge to targeted immunotherapies which may be overcome by γ‐secretase inhibitors and targeting multiple antigens,207, 208, 209 whereas venetoclax (a BCL2 inhibitor) in combination with bortezomib in relapsed/refractory MM results in improved progression‐free survival, the development of treatment‐emergent fatal infections led to the trial closing early.210. The gene discussed is TNFRSF17; the disease is infection.